Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q1 2024 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, May 10, 2024
Slide 1: Q1 FY2024
(6) SANUWAVE Wound Care Technologies Q1 FY2024 May 10, 2024
Slide 2: Live Presentation and Dial-in Information
Live Presentation Friday, May 10, 2024, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1665712&tp_key=5ceebf04ab Replay Dial-in Informa
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, plans for future business development
Slide 4: Financials Q1 2024
4 Financials Q1 2024 Consistent topline growth while managing operating cost (in millions) Q1 2024 Q1 2023 YoY Revenue $5.8 $3.8 + 53% Gross Profit $4.2 $2.5 + 68% Gross Margin 73% 67% +600bp Operating Expense $5.3 $4.5 +17% Revenue Gross Profit Operating L o s s Operating Income ($1.1) ($2.0) +47%
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth throughout 2023. Strong year on year growth in Q1 2024. $4.5 + 64% yoy • 709 Active Systems* in $4.0 +14% seq the field at end Q1 $3.5 +81% yoy • In Q1 : 43 systems sold (50%) seq $3.0 (vs 28 in Q1 2023 and 79 $2.5 i
Slide 7: Q2 and FY 2024 Revenue Guidance
7 Q2 and FY 2024 Revenue Guidance Q2 2024 FY 2024 REVENUE GROWTH REVENUE GROWTH +45-55% +50% Vs Vs Q2 2023 REVENUE FY 2023 REVENUE Of $4.7 million Of $20.4 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr